Why did Novo Nordisk sue Hims & Hers?

Novo Nordisk sued Hims & Hers for allegedly selling unapproved, compounded versions of its weight-loss and diabetes drugs, Wegovy and Ozempic.

What are the concerns about Hims & Hers' compounded drugs?

Novo Nordisk claims these compounded semaglutide products contain high impurity levels, posing risks such as severe immune reactions and overdoses.

What is the FDA's stance on compounded GLP-1 drugs?

The FDA has stated it cannot verify the quality, safety, or efficacy of compounded GLP-1 drugs being mass marketed by telehealth platforms.

Home / Business and Economy / Novo Nordisk Sues Hims & Hers Over Unapproved Weight Drugs

Novo Nordisk Sues Hims & Hers Over Unapproved Weight Drugs

9 Feb

•

Summary

Novo Nordisk alleges Hims & Hers sold unapproved weight-loss drugs.
High impurity levels found in Hims' compounded semaglutide products.
Regulators warn against unapproved GLP-1 drugs due to safety concerns.

Novo Nordisk Sues Hims & Hers Over Unapproved Weight Drugs

US drugmaker Novo Nordisk has initiated legal action against telehealth company Hims & Hers, alleging the illegal sale of unapproved weight-loss and diabetes medications. The lawsuit centers on compounded semaglutide products, which Novo Nordisk claims infringe on its patents and bypass FDA approval processes.

Novo Nordisk asserts that Hims & Hers is marketing these "knock-off" versions as safe and effective alternatives, despite lacking regulatory clearance. Testing by Novo Nordisk reportedly found significant impurity levels, raising concerns about patient safety, including potential immune reactions and overdoses.